Invasive group A streptococcal disease surveillance in Canada, 2021-2022
Invasive group A streptococcal (iGAS, ) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics, types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022. The Public Health Agency of Canada's National Microb...
Gespeichert in:
| Veröffentlicht in: | Canada communicable disease report 2024-05, Vol.50 (5), p.135-143 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 143 |
|---|---|
| container_issue | 5 |
| container_start_page | 135 |
| container_title | Canada communicable disease report |
| container_volume | 50 |
| creator | Golden, Alyssa R Griffith, Averil Tyrrell, Gregory J Kus, Julianne V McGeer, Allison Domingo, Marc-Christian Hoang, Linda Minion, Jessica Van Caeseele, Paul Smadi, Hanan Haldane, David Yu, Yang Ding, Xiaofeng Steven, Laura McFadzen, Jan Primeau, Courtney Franklin, Kristyn Martin, Irene |
| description | Invasive group A streptococcal (iGAS,
) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics,
types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022.
The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive
.
typing was performed using the Centers for Disease Control and Prevention
sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants.
Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant
type overall in 2021 and 2022 was
49, at 21.5% (n=468) and 16.9% (n=444), respectively, representing a significant increase in prevalence since 2018 ( |
| doi_str_mv | 10.14745/ccdr.v50i05a03 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128890994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2673-3729814b4c5848a5460172632d0074c48b9a95bf290e36443ea53c7b19afe5f13</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMotlbP3mTBiwe3zeRjNzmJFLWFghc9h2w2W1O2m5p0F_zvXW0t6mVmYH7zmMdD6BLwGFjO-MSYMow7jh3mGtMjNAQmIBWcwnE_gxApg0wO0FmMK4xJxjN6igZUCMo5hiGazZtOR9fZZBl8u0nuk7gNdrP1xhuj66R00epok9iGzrq61o2xiWuSqW50qW8TggmkfSHn6KTSdbQX-z5Cr48PL9NZunh-mk_vF6khWU5TmhMpgBXMcMGE5izDkJOMkhLjnBkmCqklLyoisaUZY9RqTk1egNSV5RXQEbrb6W7aYm1LY5tt0LXaBLfW4UN57dTfTePe1NJ3CgCYzAXtFW72CsG_tzZu1dpFY7-8Wd9GRXHGJCEC5z16_Q9d-TY0vT9FgQghsZSspyY7ygQfY7DV4RvA6jsm9RWTOsTUX1z9NnHgf3Khn6S9jHY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128890994</pqid></control><display><type>article</type><title>Invasive group A streptococcal disease surveillance in Canada, 2021-2022</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Golden, Alyssa R ; Griffith, Averil ; Tyrrell, Gregory J ; Kus, Julianne V ; McGeer, Allison ; Domingo, Marc-Christian ; Hoang, Linda ; Minion, Jessica ; Van Caeseele, Paul ; Smadi, Hanan ; Haldane, David ; Yu, Yang ; Ding, Xiaofeng ; Steven, Laura ; McFadzen, Jan ; Primeau, Courtney ; Franklin, Kristyn ; Martin, Irene</creator><creatorcontrib>Golden, Alyssa R ; Griffith, Averil ; Tyrrell, Gregory J ; Kus, Julianne V ; McGeer, Allison ; Domingo, Marc-Christian ; Hoang, Linda ; Minion, Jessica ; Van Caeseele, Paul ; Smadi, Hanan ; Haldane, David ; Yu, Yang ; Ding, Xiaofeng ; Steven, Laura ; McFadzen, Jan ; Primeau, Courtney ; Franklin, Kristyn ; Martin, Irene</creatorcontrib><description>Invasive group A streptococcal (iGAS,
) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics,
types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022.
The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive
.
typing was performed using the Centers for Disease Control and Prevention
sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants.
Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant
type overall in 2021 and 2022 was
49, at 21.5% (n=468) and 16.9% (n=444), respectively, representing a significant increase in prevalence since 2018 (
<0.0001). The former most prevalent type,
1, increased from 0.5% (n=10) in 2021 to 4.8% (n=125) in 2022; similarly,
12 increased from 1.0% (n=22) in 2021 to 5.8% (n=151) in 2022. These two types together accounted for almost 25% of isolates collected in late 2022 (October to December). Antimicrobial resistance rates in 2021 and 2022 included: 14.9%/14.1% erythromycin resistance, 4.8%/3.0% clindamycin resistance, and <1% chloramphenicol resistance.
The increase of iGAS isolates collected in Canada is an important public health concern. Continued surveillance of iGAS is critical to monitor expanding
types and antimicrobial resistance patterns.</description><identifier>ISSN: 1188-4169</identifier><identifier>ISSN: 1481-8531</identifier><identifier>EISSN: 1481-8531</identifier><identifier>DOI: 10.14745/ccdr.v50i05a03</identifier><identifier>PMID: 38835501</identifier><language>eng</language><publisher>Canada: Public Health Agency of Canada</publisher><subject>Age groups ; Antimicrobial agents ; Antimicrobial resistance ; COVID-19 ; Demographics ; Diffusion rate ; Disease control ; Disease resistance ; Disease transmission ; Drug resistance ; Gene sequencing ; Genomes ; Health surveillance ; Medical laboratories ; Microbiology ; Necrotizing fasciitis ; Pandemics ; Population ; Public health ; Streptococcus infections ; Surveillance ; Trends ; Whole genome sequencing</subject><ispartof>Canada communicable disease report, 2024-05, Vol.50 (5), p.135-143</ispartof><rights>2024. This work is published under https://creativecommons.org/licenses/by/4.0/deed.en (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 Public Health Agency of Canada</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2673-3729814b4c5848a5460172632d0074c48b9a95bf290e36443ea53c7b19afe5f13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149783/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149783/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38835501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Griffith, Averil</creatorcontrib><creatorcontrib>Tyrrell, Gregory J</creatorcontrib><creatorcontrib>Kus, Julianne V</creatorcontrib><creatorcontrib>McGeer, Allison</creatorcontrib><creatorcontrib>Domingo, Marc-Christian</creatorcontrib><creatorcontrib>Hoang, Linda</creatorcontrib><creatorcontrib>Minion, Jessica</creatorcontrib><creatorcontrib>Van Caeseele, Paul</creatorcontrib><creatorcontrib>Smadi, Hanan</creatorcontrib><creatorcontrib>Haldane, David</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Ding, Xiaofeng</creatorcontrib><creatorcontrib>Steven, Laura</creatorcontrib><creatorcontrib>McFadzen, Jan</creatorcontrib><creatorcontrib>Primeau, Courtney</creatorcontrib><creatorcontrib>Franklin, Kristyn</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><title>Invasive group A streptococcal disease surveillance in Canada, 2021-2022</title><title>Canada communicable disease report</title><addtitle>Can Commun Dis Rep</addtitle><description>Invasive group A streptococcal (iGAS,
) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics,
types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022.
The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive
.
typing was performed using the Centers for Disease Control and Prevention
sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants.
Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant
type overall in 2021 and 2022 was
49, at 21.5% (n=468) and 16.9% (n=444), respectively, representing a significant increase in prevalence since 2018 (
<0.0001). The former most prevalent type,
1, increased from 0.5% (n=10) in 2021 to 4.8% (n=125) in 2022; similarly,
12 increased from 1.0% (n=22) in 2021 to 5.8% (n=151) in 2022. These two types together accounted for almost 25% of isolates collected in late 2022 (October to December). Antimicrobial resistance rates in 2021 and 2022 included: 14.9%/14.1% erythromycin resistance, 4.8%/3.0% clindamycin resistance, and <1% chloramphenicol resistance.
The increase of iGAS isolates collected in Canada is an important public health concern. Continued surveillance of iGAS is critical to monitor expanding
types and antimicrobial resistance patterns.</description><subject>Age groups</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>COVID-19</subject><subject>Demographics</subject><subject>Diffusion rate</subject><subject>Disease control</subject><subject>Disease resistance</subject><subject>Disease transmission</subject><subject>Drug resistance</subject><subject>Gene sequencing</subject><subject>Genomes</subject><subject>Health surveillance</subject><subject>Medical laboratories</subject><subject>Microbiology</subject><subject>Necrotizing fasciitis</subject><subject>Pandemics</subject><subject>Population</subject><subject>Public health</subject><subject>Streptococcus infections</subject><subject>Surveillance</subject><subject>Trends</subject><subject>Whole genome sequencing</subject><issn>1188-4169</issn><issn>1481-8531</issn><issn>1481-8531</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkc1LAzEQxYMotlbP3mTBiwe3zeRjNzmJFLWFghc9h2w2W1O2m5p0F_zvXW0t6mVmYH7zmMdD6BLwGFjO-MSYMow7jh3mGtMjNAQmIBWcwnE_gxApg0wO0FmMK4xJxjN6igZUCMo5hiGazZtOR9fZZBl8u0nuk7gNdrP1xhuj66R00epok9iGzrq61o2xiWuSqW50qW8TggmkfSHn6KTSdbQX-z5Cr48PL9NZunh-mk_vF6khWU5TmhMpgBXMcMGE5izDkJOMkhLjnBkmCqklLyoisaUZY9RqTk1egNSV5RXQEbrb6W7aYm1LY5tt0LXaBLfW4UN57dTfTePe1NJ3CgCYzAXtFW72CsG_tzZu1dpFY7-8Wd9GRXHGJCEC5z16_Q9d-TY0vT9FgQghsZSspyY7ygQfY7DV4RvA6jsm9RWTOsTUX1z9NnHgf3Khn6S9jHY</recordid><startdate>20240524</startdate><enddate>20240524</enddate><creator>Golden, Alyssa R</creator><creator>Griffith, Averil</creator><creator>Tyrrell, Gregory J</creator><creator>Kus, Julianne V</creator><creator>McGeer, Allison</creator><creator>Domingo, Marc-Christian</creator><creator>Hoang, Linda</creator><creator>Minion, Jessica</creator><creator>Van Caeseele, Paul</creator><creator>Smadi, Hanan</creator><creator>Haldane, David</creator><creator>Yu, Yang</creator><creator>Ding, Xiaofeng</creator><creator>Steven, Laura</creator><creator>McFadzen, Jan</creator><creator>Primeau, Courtney</creator><creator>Franklin, Kristyn</creator><creator>Martin, Irene</creator><general>Public Health Agency of Canada</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M3G</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240524</creationdate><title>Invasive group A streptococcal disease surveillance in Canada, 2021-2022</title><author>Golden, Alyssa R ; Griffith, Averil ; Tyrrell, Gregory J ; Kus, Julianne V ; McGeer, Allison ; Domingo, Marc-Christian ; Hoang, Linda ; Minion, Jessica ; Van Caeseele, Paul ; Smadi, Hanan ; Haldane, David ; Yu, Yang ; Ding, Xiaofeng ; Steven, Laura ; McFadzen, Jan ; Primeau, Courtney ; Franklin, Kristyn ; Martin, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2673-3729814b4c5848a5460172632d0074c48b9a95bf290e36443ea53c7b19afe5f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age groups</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>COVID-19</topic><topic>Demographics</topic><topic>Diffusion rate</topic><topic>Disease control</topic><topic>Disease resistance</topic><topic>Disease transmission</topic><topic>Drug resistance</topic><topic>Gene sequencing</topic><topic>Genomes</topic><topic>Health surveillance</topic><topic>Medical laboratories</topic><topic>Microbiology</topic><topic>Necrotizing fasciitis</topic><topic>Pandemics</topic><topic>Population</topic><topic>Public health</topic><topic>Streptococcus infections</topic><topic>Surveillance</topic><topic>Trends</topic><topic>Whole genome sequencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Griffith, Averil</creatorcontrib><creatorcontrib>Tyrrell, Gregory J</creatorcontrib><creatorcontrib>Kus, Julianne V</creatorcontrib><creatorcontrib>McGeer, Allison</creatorcontrib><creatorcontrib>Domingo, Marc-Christian</creatorcontrib><creatorcontrib>Hoang, Linda</creatorcontrib><creatorcontrib>Minion, Jessica</creatorcontrib><creatorcontrib>Van Caeseele, Paul</creatorcontrib><creatorcontrib>Smadi, Hanan</creatorcontrib><creatorcontrib>Haldane, David</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Ding, Xiaofeng</creatorcontrib><creatorcontrib>Steven, Laura</creatorcontrib><creatorcontrib>McFadzen, Jan</creatorcontrib><creatorcontrib>Primeau, Courtney</creatorcontrib><creatorcontrib>Franklin, Kristyn</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>CBCA Reference & Current Events</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canada communicable disease report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Golden, Alyssa R</au><au>Griffith, Averil</au><au>Tyrrell, Gregory J</au><au>Kus, Julianne V</au><au>McGeer, Allison</au><au>Domingo, Marc-Christian</au><au>Hoang, Linda</au><au>Minion, Jessica</au><au>Van Caeseele, Paul</au><au>Smadi, Hanan</au><au>Haldane, David</au><au>Yu, Yang</au><au>Ding, Xiaofeng</au><au>Steven, Laura</au><au>McFadzen, Jan</au><au>Primeau, Courtney</au><au>Franklin, Kristyn</au><au>Martin, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Invasive group A streptococcal disease surveillance in Canada, 2021-2022</atitle><jtitle>Canada communicable disease report</jtitle><addtitle>Can Commun Dis Rep</addtitle><date>2024-05-24</date><risdate>2024</risdate><volume>50</volume><issue>5</issue><spage>135</spage><epage>143</epage><pages>135-143</pages><issn>1188-4169</issn><issn>1481-8531</issn><eissn>1481-8531</eissn><abstract>Invasive group A streptococcal (iGAS,
) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics,
types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022.
The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive
.
typing was performed using the Centers for Disease Control and Prevention
sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants.
Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant
type overall in 2021 and 2022 was
49, at 21.5% (n=468) and 16.9% (n=444), respectively, representing a significant increase in prevalence since 2018 (
<0.0001). The former most prevalent type,
1, increased from 0.5% (n=10) in 2021 to 4.8% (n=125) in 2022; similarly,
12 increased from 1.0% (n=22) in 2021 to 5.8% (n=151) in 2022. These two types together accounted for almost 25% of isolates collected in late 2022 (October to December). Antimicrobial resistance rates in 2021 and 2022 included: 14.9%/14.1% erythromycin resistance, 4.8%/3.0% clindamycin resistance, and <1% chloramphenicol resistance.
The increase of iGAS isolates collected in Canada is an important public health concern. Continued surveillance of iGAS is critical to monitor expanding
types and antimicrobial resistance patterns.</abstract><cop>Canada</cop><pub>Public Health Agency of Canada</pub><pmid>38835501</pmid><doi>10.14745/ccdr.v50i05a03</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1188-4169 |
| ispartof | Canada communicable disease report, 2024-05, Vol.50 (5), p.135-143 |
| issn | 1188-4169 1481-8531 1481-8531 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149783 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Age groups Antimicrobial agents Antimicrobial resistance COVID-19 Demographics Diffusion rate Disease control Disease resistance Disease transmission Drug resistance Gene sequencing Genomes Health surveillance Medical laboratories Microbiology Necrotizing fasciitis Pandemics Population Public health Streptococcus infections Surveillance Trends Whole genome sequencing |
| title | Invasive group A streptococcal disease surveillance in Canada, 2021-2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A12%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Invasive%20group%20A%20streptococcal%20disease%20surveillance%20in%20Canada,%202021-2022&rft.jtitle=Canada%20communicable%20disease%20report&rft.au=Golden,%20Alyssa%20R&rft.date=2024-05-24&rft.volume=50&rft.issue=5&rft.spage=135&rft.epage=143&rft.pages=135-143&rft.issn=1188-4169&rft.eissn=1481-8531&rft_id=info:doi/10.14745/ccdr.v50i05a03&rft_dat=%3Cproquest_pubme%3E3128890994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128890994&rft_id=info:pmid/38835501&rfr_iscdi=true |